



## **KineMed to Present at Rodman & Renshaw 8<sup>th</sup> Annual Healthcare Conference**

**Emeryville, Calif.**, October 31, 2006 – KineMed Inc., a privately held pathway-based drug discovery and development company announced today that David M. Fineman, CEO and President of KineMed, will present an overview of the company and its drug development programs at the 8<sup>th</sup> Annual Rodman & Renshaw Healthcare Conference in New York on Wednesday, November 8<sup>th</sup> at 4:10 p.m. EST. In addition to providing a general corporate update, Mr. Fineman will discuss a new product under development for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.

The presentation will be webcast live and will be available at <http://www.wsw.com/webcast/rshq10/kinemed>. It will also be archived for a limited time after the presentation and will be available on the company's website at [www.kinemed.com](http://www.kinemed.com).

### **About KineMed**

KineMed, Inc. is a pathway-based drug discovery and development company employing its proprietary biomarker technology (AquaTag™ and KineMarker™) to measure the real-time activity of drugs in whole body systems. KineMed is developing therapeutics both on its own and with pharmaceutical collaborators, efficiently translating compounds into drugs with a desired biological effect on validated disease pathways. KineMed's technology expedites the drug development process and has demonstrated results in metabolic disorders, neurodegeneration, diseases of inflammation and cancer, among other conditions.

For further information about KineMed, please visit: <http://www.kinemed.com/>

CONTACT KINEMED: Brent Vaughan, Chief Business Officer of KineMed Inc., +1-510-655-6525, ext. 110; or Media: Justin Jackson of Burns McClellan, [jjackson@burnsmc.com](mailto:jjackson@burnsmc.com), or Investors: John Cummings, [jcumings@burnsmc.com](mailto:jcumings@burnsmc.com), both of Burns McClellan, +1-212-213-0006, both for KineMed Inc.